Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCompany
Medica Corp
MA - Bedford
HEPARIN SODIUM (heparin sodium) by Medica Corp is protein, antithrombin iii, to induce a conformational change, which markedly enhances the serine protease activity of antithrombin iii, thereby inhibiting the activated coagulation factors involved in the clotting sequence, particularly xa and iia. Approved for postoperative deep venous thrombosis, pulmonary embolism in patients undergoing major abdominothoracic surgery, for other reasons and 4 more indications. First approved in 2020.
Drug data last refreshed 19h ago
protein, Antithrombin III, to induce a conformational change, which markedly enhances the serine protease activity of Antithrombin III, thereby inhibiting the activated coagulation factors involved in the clotting sequence, particularly Xa and IIa. Small amounts of heparin inhibit Factor Xa, and…
Worked on HEPARIN SODIUM at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Study With Heparin Sodium in Subcutaneous Administration
Study With Heparin Sodium in Intravenous Administration
Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo